MOLECULAR PHARMACOLOGY LIMITED
Breaking Through the Pain Barrier
Molecular Pharmacology (USA) Limited, (MPL-USA) is a public, biotechnology company (OTCBB: MLPH) dedicated to the discovery and development of analgesic and anti-inflammatory products based on the proprietary MPL-TL (tripeptofen) compound. MPL-TL, an oligopeptide, is a new key active ingredient that targets a different part of the pain and inflammation cascade than other analgesic/anti-inflammatory drugs. It is the first significant new topical analgesic discovery in nearly 50 years and will drive new products and opportunity in the $36.5 billion analgesia and anti-inflammatory industry. Delivered through the skin, analgesic products based on MPL-TL are expected to be fast acting with localized effects and minimal anticipated drug interactions or side effects .
MPL USA holds the exclusive worldwide rights to develop new and fast-acting analgesic and anti-inflammatory products based on MPL-TL . The parent product for MPL-TL has been used and tested for nearly two decades and has been shown to be fast acting , safe and effective.
MPL's primary objectives are to:
• Refine and bring to clinical trials the first new class of analgesics in several decades.
• Gain American, Australian & European regulatory and marketing approval.
• Manufacture, sell or license MPL-TL as a new, key active ingredient.
MPL-TL100 is the first candidate complex based on MPL-TL. It is currently being tested in human clinical trials for lateral epicondylitis (tennis elbow).
(This link goes directly to MLPH's Platform Description)
MANAGEMENT Jeff Edwards, Technical Operations Development
Drug Discovery Research Centre
284 Oxford Street
Perth, WA 6007
Jeff Edwards has over twenty years experience in managing new technological innovations. He is experienced in production, intellectual property, regulatory affairs and quality systems. He is an award winning technology developer in his own right, and has worked across a range of medical and technology fields with organizations including Omni LifeScience, Genesis Biomedical, CollTech Australia, IBM, NCR and Intellect Electronics. Dr. Maud Eijkenboom
Dr. Eikenboom is a consulting neuroscientist specialising in chronic neuropathic and inflammatory pain. She brings 8 years of expertise managing many of the preclinical studies in animals and clinical development aspects for Bayer Healthcare of Germany. Dr Eikenboom has worked in the Netherlands, Russia, Germany and Brazil and has recently settled in Australia. Dr. Sal Abdi, Consultant
Dr. Sal Abdi is currently the Chief (LOA) of the Division of Pain Medicine in the Dept. of Anesthesiology, Perioperative Medicine and Pain Management; Professor, Clinical Anesthesiology; Director, Fellowship Program in Pain Medicine; and Medical Director, JMH University of Miami School of Medicine in Miami, Florida and Director of the Massachusetts General Hospital Pain Center Dept. of Anesthesia and Critical Care at MGH; and Assoc. Prof. Anesthesiology (Pending) at Harvard Medical School in Boston, Massachusetts. He is currently licensed in Massachusetts, Texas & Florida. Dr. Chris Quirk, Dermatology and Clinical Medicine
Dr. Quirk is an Australian dermatologist who has been a teaching hospital consultant for 21 years and has conducted numerous trials for international pharmaceutical companies such as Roche, Novartis, 3M and Matrix and has served on advisory boards for Merck, Allergan and Roche. He has published 22 papers in international journals and most recently has presented at the World Congress of Dermatology in Paris and the World Congress on Cancers of the Skin in Seville.
Molecular Pharmacology (USA) Limited